

MAY. 4. 2006 5:47PM

NO. 4144 P. 2  
Sheet 1 of 8

APPLICANT PAGEABLE OF FORM PTO-1204 REV 7-00	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. <b>BBI-6077CP</b>	SERIAL NO. <b>09/777,554</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>Cusack, K. P. et al.</b>	
		FILED DATE <b>February 8, 2001</b>	GROUP <b>1626</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPROPRIATE
RS	A1	4,966,849	10/90	Vallee et al.	435	199	
RS	A2	5,217,999	06/93	Levitzki et al.	514	613	
RS	A3	5,302,606	04/94	Spada et al.	514	357	
RS	A4	5,330,992	07/94	Eissenstat et al.	514	312	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
RS	A5	WO 91/15495 A1	10/91	PCT				
	A6	WO 92/20642 A1	11/92	PCT				
	A7	WO 92/21660 A1	12/92	PCT				
	A8	WO 94/03427 A1	02/94	PCT				
	A9	WO 94/10202 A1	05/94	PCT				
	A10	WO 94/14808 A1	07/94	PCT				
	A11	EP 566 226 B1	11/95	EPO				
	A12	WO 97/22596 A1	06/97	PCT				
	A13	WO 97/34876 A1	09/97	PCT				
	A14	WO97/40830 A1	11/97	PCT				
	A15	WO 97/40831 A1	11/97	PCT				
	A16	WO 97/42187 A1	11/97	PCT				
RS	A17	WO 98/07832 A1	02/98	PCT				

## OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

RS	A18	<i>Expert Opin. Ther. Pat.</i> 8(4): 475-478 (1998)
	A19	Achen <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," <i>PNAS USA</i> 95(2): 548-553 (1998)
	A20	Aplin <i>et al.</i> , "In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta," <i>Journal of Neurochemistry</i> , 67:699-707 (1996)
	A21	Armstrong, "Treatment of opportunistic fungal infections," <i>Clinical Infectious Diseases</i> , 16:1-7. (1993)
	A22	Badger <i>et al.</i> , "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 279:1453-1461 (1996)
Examiner		Date Considered
		/Rei Tsang Shiao/ (05/15/2006)
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

MAY. 4. 2006 5:48PM

NO. 4144 P. 3 of 6

APPLICANT FOLDER OF FORM PTO-1481 REV 7-90	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. <b>BBI-6077CP</b>	SERIAL NO. <b>09/777,554</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>Cusack, K. P. et al.</b>	
		FILING DATE <b>February 8, 2001</b>	GROUP <b>1626</b>

## OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

RS	B1	Baeuerle <i>et al.</i> , "Function and activation of NF-kappa B in the immune system," <i>Annual Review of Immunology</i> , 12:141-179 (1994)
	B2	Beg <i>et al.</i> , "An essential role for NF-kappaB in preventing TNF-alpha-induced cell death," <i>Science</i> , 274:782-784 (1996)
	B3	Bolen, "Nonreceptor tyrosine protein kinases," <i>Oncogene</i> 8:2025-2031 (1993)
	B4	Borthwick <i>et al.</i> , "Inhibition of glycogen synthase kinase-3 by insulin in cultured human skeletal muscle myoblasts," <i>Biochemical &amp; Biophysical Research Communications</i> , 210:738-745 (1995)
	B5	Brickell, "The p60c-src family of protein-tyrosine kinases: structure, regulation, and function," <i>Critical Reviews in Oncogenesis</i> , 3:401-406 (1992)
	B6	Brown <i>et al.</i> , <i>Regulation of Angiogenesis</i> (ed. L.D. Goldberg and E.M. Rosen), 233-269 (1997)
	B7	Buchdunger <i>et al.</i> , "Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class," <i>PNAS USA</i> , 92:2258-2262 (1995)
	B8	Courtneidge, "Protein tyrosine kinases, with emphasis on the Src family," <i>Seminars in Cancer Biology</i> , 5:236-246 (1994)
	B9	Cowburn, "Peptide recognition by PTB and PDZ domains," <i>Curr. Opin. Struct. Biol.</i> , 7(6):835-838 (1997)
	B10	De Vries <i>et al.</i> , "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor," <i>Science</i> 255:989-991 (1992)
	B11	Draetta, "Cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation," <i>Trends in Cell Biology</i> , 3:287-289 (1993)
	B12	Ducommun <i>et al.</i> , "cdc2 phosphorylation is required for its interaction with cyclin," <i>EMBO Journal</i> , 10:3311-3319 (1991)
	B13	Fantl <i>et al.</i> , "Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways," <i>Cell</i> 69:413-423 (1992)
	B14	Ferrara <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cell. Biochem.</i> 47:211-218 (1991)
	B15	Ferrara <i>et al.</i> , "Vascular endothelial growth factor: Basic biology and clinical implications," in <i>Regulation of Angiogenesis</i> (ed. L. D. Goldberg and E.M. Rosen), 209-232 (1997)
	B16	Ferrara <i>et al.</i> , "The biology of vascular endothelial growth factor," <i>Endocrine Reviews</i> 18(1): 4-25 (1997)
	B17	Gautier <i>et al.</i> , "Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle," <i>Nature</i> 339:626-629 (1989)
	B18	Gilbert, "Horizontal integration and cortical dynamics," <i>Neuron</i> 9:1-13 (1992)
RS	B19	Girard <i>et al.</i> , "Cyclin A is required for the onset of DNA replication in mammalian fibroblasts," <i>Cell</i> , 67:1169-1179 (1991)
Examiner		Date Considered
		/Rei Tsang Shiao/ (05/15/2006)
EXAMINER:		
Initial if reference considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

APPLICANT PAGE NO. OF FORM PTO-1443 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. <b>BBI-6077CP</b>	SERIAL NO. <b>09/777,554</b>
<b>LIST OF PUBLICATIONS CITED BY APPLICANT</b> (Use several sheets if necessary)		APPLICANT <b>Cusack, K. P. et al.</b>	
FILING DATE <b>February 8, 2001</b>		GROUP <b>1626</b>	

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RS	C1	Gould et al., "Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis," <i>Nature</i> , 342:39-45 (1989)
	C2	He et al., "The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines," <i>Journal of Virology</i> , 71:405-411 (1997)
	C3	Hosoi et al., "Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract," <i>Journal of Biochemistry (Tokyo)</i> , 117:741-749 (1995)
	C4	Hunter et al., "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," <i>Cell</i> , 79:573-582 (1994)
	C5	Jakeman et al., "Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis," <i>Endocrinology</i> 133: 848-859 (1993)
	C6	Jellinek et al., "Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor," <i>Biochemistry</i> 33:10450-56 (1994)
	C7	Kendall et al., "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <i>Proc. Natl. Acad. Sci</i> 90:10705-09 (1994)
	C8	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," <i>Nature</i> 362:841-844 (1993)
	C9	Kinsella, et al. "Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel," <i>Exp. Cell Res.</i> 199:56-62 (1992)
	C10	Klagsburn et al., "Vascular endothelial growth factor and its receptors," <i>Cytokine &amp; Growth Factor Reviews</i> 7: 259-270 (1996)
	C11	Koch et al., "SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins," <i>Science</i> 252:668-678 (1991)
	C12	Kohn et al., "Cell cycle control and cancer chemotherapy," <i>Journal of Cellular Biochemistry</i> , 54:440-452 (1994)
	C13	Kolch et al., "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis," <i>Breast Cancer Research and Treatment</i> 36: 139-155 (1996)
	C14	Korpelainen et al., "Signaling angiogenesis and lymphangiogenesis," <i>Curr. Opin. Cell Biol.</i> , 10:159-164 (1998)
	C15	Krek et al., "Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates," <i>EMBO Journal</i> , 10:3331-3341 (1991)
	C16	Lees, "Cyclin dependent kinase regulation," <i>Current Opinion in Cell Biology</i> , 7:773-780 (1995)
	C17	Lymboussaki et al., "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors," <i>Am. J. Pathol.</i> 153(2): 395-403 (1998)
	C18	Magillone et al., "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-31 (1993)
	C19	Mariani, et al., "Inhibition of angiogenesis by FCE 25806, a potent tyrosine kinase inhibitor," <i>Proc. Am. Assoc. Cancer Res.</i> 35:2268 (1994)
V RS	C20	Matsushima et al., "D-type cyclin-dependent kinase activity in mammalian cells," <i>Molecular &amp; Cellular Biology</i> , 14:2066-2076 (1994)
Examiner		Date Considered
/Rei Tsang Sh		ao/ (05/15/2006)
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

MAY. 4. 2006 5:48PM

NO. 4144 P. 5  
Sheet 5 of 8

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-90	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. <b>BBI-6077CP</b>	SERIAL NO. <b>09/777,554</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>Cusack, K. P. et al.</b>	
		FILING DATE <b>February 6, 2001</b>	DRAWING <b>1626</b>

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RS	D1	Matthews <i>et al.</i> , "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit," <i>PNAS USA</i> , 88:9026-30 (1991)
	D2	Meyer <i>et al.</i> , "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases," <i>EMBO J.</i> 18(2):363-374 (1999)
	D3	Migdal <i>et al.</i> , "Neuropilin-1 is a placenta growth factor-2 receptor," <i>J. Biol. Chem.</i> 273 (35): 22272-22278 (1998)
	D4	Millauer <i>et al.</i> , "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> 72:835-846 (1993)
	D5	Murray <i>et al.</i> , "Cyclin synthesis drives the early embryonic cell cycle," <i>Nature</i> , 339:275-280 (1989)
	D6	Mustonen <i>et al.</i> , "Endothelial receptor tyrosine kinases involved in angiogenesis," <i>J. Cell Biol.</i> 129:895-898 (1995)
	D7	Myers <i>et al.</i> , "The preparation and synthesis of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines; inhibitors of p56 <sup>lck</sup> and EGF-R tyrosine kinase activity," <i>Bioorg. Med. Chem. Lett.</i> 7:417-420 (1997)
	D8	Myers <i>et al.</i> , "The synthesis and synthesis of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 7:421-424 (1997)
	D9	Oelrichs <i>et al.</i> , "NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo," <i>Oncogene</i> 8(1):11-15 (1993)
	D10	Ogawa <i>et al.</i> , "A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain," <i>J. Biol. Chem.</i> 273(47): 31273-31282 (1998)
	D11	Ohtsubo <i>et al.</i> , "Cyclin-dependent regulation of G1 in mammalian fibroblasts," <i>Science</i> , 259:1908-1912 (1993)
	D12	Osmani <i>et al.</i> , "Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in <i>A. nidulans</i> ," <i>Cell</i> , 67:283-291 (1991)
	D13	Osmani <i>et al.</i> , "Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint," <i>EMBO Journal</i> , 10:2669-2679 (1991)
	D14	Pagano <i>et al.</i> , "Cyclin A is required at two points in the human cell cycle," <i>EMBO Journal</i> , 11:961-971 (1992)
	D15	Park <i>et al.</i> , "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR," <i>J. Biol. Chem.</i> 269:25646-54 (1994)
RS	D16	Perkins <i>et al.</i> , "Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator," <i>Science</i> , 275:523-527 (1997)
Examiner		Date Considered
/Rei Tsang		Shiao/ (05/15/2006)
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

APPLICANT FACSIMILE OF FORM PTO-1444 REV 7-90	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO <b>BBI-6077CP</b>	SERIAL NO <b>09/777,554</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>Cusack, K. P. et al.</b>	
FILING DATE <b>February 8, 2001</b>		GROUP <b>1626</b>	

## OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

RS	E1	Pines, "Cell proliferation and control," <i>Current Opinion in Cell Biology</i> , 4:144-148 (1992)
	E2	Pines, "Cyclins and cyclin-dependent kinases: take your partners," <i>Trends in Biochemical Sciences</i> , 18:195-197 (1993)
	E3	Powis, "Signalling pathways as targets for anticancer drug development," <i>Pharmacology &amp; Therapeutics</i> , 62:57-95 (1994)
	E4	Quelle <i>et al.</i> , "Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts," <i>Genes &amp; Development</i> , 7:1559-1571 (1993)
	E5	Resnitzky <i>et al.</i> , "Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system," <i>Molecular &amp; Cellular Biology</i> , 14:1669-1679 (1994)
	E6	Ristimaki <i>et al.</i> , "Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C," <i>J. Biol. Chem.</i> 273(14):8413-8418 (1998)
	E7	Rosenblatt <i>et al.</i> , "Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A," <i>Proc. Nat Acad. Sc. USA</i> , 89:2824-2828 (1992)
	E8	Schlessinger <i>et al.</i> , "Growth factor signaling by receptor tyrosine kinases," <i>Neuron</i> 9:383-391 (1992)
	E9	Shawver <i>et al.</i> , "Receptor tyrosine kinases as targets for inhibition of angiogenesis," <i>Drug Discovery Today</i> , 2:60-63 (1997)
	E10	Sherr, "Mammalian G1 cyclins," <i>Cell</i> , 73:1059-1065 (1993)
	E11	Shibuya <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (ft) closely related to the fms family," <i>Oncogene</i> 5:519-524 (1990)
	E12	Shoelson, "SH2 and PTB domain interactions in tyrosine kinase signal transduction," <i>Curr. Opin. Chem. Biol.</i> 1(2): 227-234 (1997)
	E13	Solomon <i>et al.</i> , "Cyclin activation of p34cdc2," <i>Cell</i> , 63:1013-1024 (1990)
	E14	Solomon <i>et al.</i> , "Role of phosphorylation in p34cdc2 activation: identification of an activating kinase," <i>Molecular Biology of the Cell</i> , 3:13-27 (1992)
	E15	Songyang <i>et al.</i> , "SH2 domains recognize specific phosphopeptide sequences," <i>Cell</i> 72:767-778 (1993)
	E16	Songyang <i>et al.</i> , "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav," <i>Mol. Cell. Biol.</i> 14:2777-2785 (1994)
	E17	Staunton <i>et al.</i> , "The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and Rhinovirus," <i>Cell</i> 61:243-254 (1990)
	E18	Stone <i>et al.</i> , "Reversible, p16-mediated cell cycle arrest as protection from chemotherapy," <i>Cancer Research</i> , 56:3189-3202 (1996)
	E19	Takano, <i>et al.</i> , "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase," <i>Mol. Bio. Cell</i> 4:358A (1993)
RS	E20	Tanaka <i>et al.</i> , "c-CBL is downstream of c-Src in a signalling pathway necessary for bone resorption," <i>Nature</i> , 383:528-531 (1996)
Examiner		Date Considered
		/Rei Tsang Shiao/ (05/15/2006)
*EXAMINER:		Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NO. 4144 P. 7  
Sheet 7 of 6

**OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)**

PAGE 7/7 \* RCVD AT 5/4/2006 4:48:03 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-2/8 \* DNIS:2730707 \* CSID:5086888110 \* DURATION (mm-ss):02:44

REV 7-90

U.S. DEPARTMENT OF  
COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 8, 2001

GROUP

1626

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RS	A1	4,966,849	10/90	Vallee et al.	435	199	
RS	A2	5,217,999	06/93	Levitzki et al.	514	613	
RS	A3	5,302,606	04/94	Spada et al.	514	357	
RS	A4	5,330,992	07/94	Eissenstat et al.	514	312	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
RS	A5	WO 91/15495 A1	10/91	PCT				
	A6	WO 92/20642 A1	11/92	PCT				
	A7	WO 92/21660 A1	12/92	PCT				
	A8	WO 94/03427 A1	02/94	PCT				
	A9	WO 94/10202 A1	05/94	PCT				
	A10	WO 94/14808 A1	07/94	PCT				
	A11	EP 566 226 B1	11/95	EPO				
	A12	WO 97/22596 A1	06/97	PCT				
	A13	WO 97/34876 A1	09/97	PCT				
	A14	WO97/40830 A1	11/97	PCT				
	A15	WO 97/40831 A1	11/97	PCT				
	A16	WO 97/42187 A1	11/97	PCT				
RS	A17	WO 98/07832 A1	02/98	PCT				

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RS	A18	Expert Opin. Ther. Pat. 8(4): 475-478 (1998)
	A19	Achen et al., "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," <i>PNAS USA</i> 95(2): 548-553 (1998)
	A20	Aplin et al., "In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta," <i>Journal of Neurochemistry</i> , 67:699-707 (1996)
	A21	Armstrong, "Treatment of opportunistic fungal infections," <i>Clinical Infectious Diseases</i> , 16:1-7. (1993)
RS	A22	Badger et al., "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 279:1453-1461 (1996)
Examiner		/Rei Tsang Shiao/ (05/15/2006)
Date Considered		(05/15/2006)
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-00

U.S. DEPARTMENT OF  
COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 8, 2001

GROUP

1626

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RS	B1	Baeuerle <i>et al.</i> , "Function and activation of NF-kappa B in the immune system," <i>Annual Review of Immunology</i> , 12:141-179 (1994)
	B2	Beg <i>et al.</i> , "An essential role for NF-kappaB in preventing TNF-alpha-induced cell death," <i>Science</i> , 274:782-784 (1996)
	B3	Bolen, "Nonreceptor tyrosine protein kinases," <i>Oncogene</i> 8:2025-2031 (1993)
	B4	Borthwick <i>et al.</i> , "Inhibition of glycogen synthase kinase-3 by insulin in cultured human skeletal muscle myoblasts," <i>Biochemical &amp; Biophysical Research Communications</i> , 210:738-745 (1995)
	B5	Brickell, "The p60c-src family of protein-tyrosine kinases: structure, regulation, and function," <i>Critical Reviews in Oncogenesis</i> , 3:401-406 (1992)
	B6	Brown <i>et al.</i> , <i>Regulation of Angiogenesis</i> (ed. L.D. Goldberg and E.M. Rosen), 233-269 (1997)
	B7	Buchdunger <i>et al.</i> , "Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class," <i>PNAS USA</i> , 92:2258-2262 (1995)
	B8	Courtneidge, "Protein tyrosine kinases, with emphasis on the Src family," <i>Seminars in Cancer Biology</i> , 5:236-246 (1994)
	B9	Cowburn, "Peptide recognition by PTB and PDZ domains," <i>Curr. Opin. Struct. Biol.</i> , 7(6):835-838 (1997)
	B10	De Vries <i>et al.</i> , "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor," <i>Science</i> 255:989-991 (1992)
	B11	Draetta, "Cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation," <i>Trends in Cell Biology</i> , 3:287-289 (1993)
	B12	Ducommun <i>et al.</i> , "cdc2 phosphorylation is required for its interaction with cyclin," <i>EMBO Journal</i> , 10:3311-3319 (1991)
	B13	Fantl <i>et al.</i> , "Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways," <i>Cell</i> 69:413-423 (1992)
	B14	Ferrara <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cell. Biochem.</i> 47:211-218 (1991)
	B15	Ferrara <i>et al.</i> , "Vascular endothelial growth factor: Basic biology and clinical implications," in <i>Regulation of Angiogenesis</i> (ed. L. D. Goldberg and E.M. Rosen), 209-232 (1997)
	B16	Ferrara <i>et al.</i> , "The biology of vascular endothelial growth factor," <i>Endocrine Reviews</i> 18(1): 4-25 (1997)
	B17	Gautier <i>et al.</i> , "Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle," <i>Nature</i> 339:626-629 (1989)
	B18	Gilbert, "Horizontal integration and cortical dynamics," <i>Neuron</i> 9:1-13 (1992)
RS	B19	Girard <i>et al.</i> , "Cyclin A is required for the onset of DNA replication in mammalian fibroblasts," <i>Cell</i> , 67:1169-1179 (1991)

Examiner

Date Considered

/Rei Tsang Shiab/ (05/15/2006)

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





APPLICANT FACSIMILE OF FORM PTO-1449  
 REV 7-80

 U.S. DEPARTMENT OF  
 COMMERCE  
 PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

SERIAL NO.

BBI-6077CP

09/777,554

 LIST OF PUBLICATIONS CITED BY APPLICANT  
 (Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 8, 2001

GROUP 1626

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RS		Gould <i>et al.</i> , "Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis," <i>Nature</i> , 342:39-45 (1989)
	C2	He <i>et al.</i> , "The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines," <i>Journal of Virology</i> , 71:405-411 (1997)
	C3	Hosoi <i>et al.</i> , "Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract," <i>Journal of Biochemistry (Tokyo)</i> , 117:741-749 (1995)
	C4	Hunter <i>et al.</i> , "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," <i>Cell</i> , 79:573-582 (1994)
	C5	Jakeman <i>et al.</i> , "Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis," <i>Endocrinology</i> 133: 848-859 (1993)
	C6	Jellinek, <i>et al.</i> , "Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor," <i>Biochemistry</i> 33:10450-56 (1994)
	C7	Kendall <i>et al.</i> , "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <i>Proc. Natl. Acad. Sci</i> 90:10705-09 (1994)
	C8	Kim <i>et al.</i> , "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," <i>Nature</i> 362:841-844 (1993)
	C9	Kinsella, <i>et al.</i> "Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel," <i>Exp. Cell Res.</i> 199:56-62 (1992)
	C10	Klagsburn <i>et al.</i> , "Vascular endothelial growth factor and its receptors," <i>Cytokine &amp; Growth Factor Reviews</i> 7: 259-270 (1996)
	C11	Koch <i>et al.</i> , "SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins," <i>Science</i> 252:668-678 (1991)
	C12	Kohn <i>et al.</i> , "Cell cycle control and cancer chemotherapy," <i>Journal of Cellular Biochemistry</i> , 54:440-452 (1994)
	C13	Kolch <i>et al.</i> , "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis," <i>Breast Cancer Research and Treatment</i> 36: 139-155 (1995)
	C14	Korpelainen <i>et al.</i> , "Signaling angiogenesis and lymphangiogenesis," <i>Curr. Opin. Cell Biol.</i> , 10:159-164 (1998)
	C15	Krek <i>et al.</i> , "Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates," <i>EMBO Journal</i> , 10:3331-3341 (1991)
	C16	Lees, "Cyclin dependent kinase regulation," <i>Current Opinion in Cell Biology</i> , 7:773-780 (1995)
	C17	Lymboussaki <i>et al.</i> , "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors," <i>Am. J. Pathol.</i> 153(2): 395-403 (1998)
	C18	Maglione <i>et al.</i> "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-31 (1993)
	C19	Mariani, <i>et al.</i> , "inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <i>Proc. Am. Assoc. Cancer Res.</i> 35:2268 (1994)
RS	C20	Matsushima <i>et al.</i> , "D-type cyclin-dependent kinase activity in mammalian cells," <i>Molecular &amp; Cellular Biology</i> , 14:2066-2076 (1994)

Examiner

Date Considered

/Rei Tsang Shiao/ (05/15/2006)

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-90

U.S. DEPARTMENT OF  
COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

BBI-6077CP

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 6, 2001

GROUP

1626

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

D1	Matthews <i>et al.</i> , "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit," <i>PNAS USA</i> , 88:9026-30 (1991)
D2	Meyer <i>et al.</i> , "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases," <i>EMBO J.</i> 18(2):363-374 (1999)
D3	Migdal <i>et al.</i> , "Neuropilin-1 is a placenta growth factor-2 receptor," <i>J. Biol. Chem.</i> 273 (35): 22272-22278 (1998)
D4	Millauer <i>et al.</i> , "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> 72:835-846 (1993)
D5	Murray <i>et al.</i> , "Cyclin synthesis drives the early embryonic cell cycle," <i>Nature</i> , 339:275-280 (1989)
D6	Mustonen <i>et al.</i> , "Endothelial receptor tyrosine kinases involved in angiogenesis," <i>J. Cell Biol.</i> 129:895-898 (1995)
D7	Myers <i>et al.</i> , "The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56 <sup>lck</sup> and EGF-R tyrosine kinase activity," <i>Bioorg. Med. Chem. Lett.</i> 7:417-420 (1997)
D8	Myers <i>et al.</i> , "The synthesis and sar of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 7:421-424 (1997)
D9	Oelrichs <i>et al.</i> , "NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo," <i>Oncogene</i> 8(1):11-15 (1993)
D10	Ogawa <i>et al.</i> , "A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain," <i>J. Biol. Chem.</i> 273(47): 31273-31282 (1998)
D11	Ohtsubo <i>et al.</i> , "Cyclin-dependent regulation of G1 in mammalian fibroblasts," <i>Science</i> , 259:1908-1912 (1993)
D12	Osmani <i>et al.</i> , "Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in <i>A. nidulans</i> ," <i>Cell</i> , 67:283-291 (1991)
D13	Osmani <i>et al.</i> , "Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint," <i>EMBO Journal</i> , 10:2669-2679 (1991)
D14	Pagano <i>et al.</i> , "Cyclin A is required at two points in the human cell cycle," <i>EMBO Journal</i> , 11:961-971 (1992)
D15	Park <i>et al.</i> , "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR," <i>J. Biol. Chem.</i> 269:25646-54 (1994)
D16	Perkins <i>et al.</i> , "Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator," <i>Science</i> , 275:523-527 (1997)

Examiner

/Rei Tsang Shiao

Date Considered

(05/15/2006)

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF  
COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

BBI-6077CP

SERIAL NO.

09/777,554

LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

Cusack, K. P. et al.

FILING DATE

February 8, 2001

GROUP 1626

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

E1	Pines, "Cell proliferation and control," <i>Current Opinion in Cell Biology</i> , 4:144-148 (1992)
E2	Pines, "Cyclins and cyclin-dependent kinases: take your partners," <i>Trends in Biochemical Sciences</i> , 18:195-197 (1993)
E3	Powis, "Signalling pathways as targets for anticancer drug development," <i>Pharmacology &amp; Therapeutics</i> , 62:57-95 (1994)
E4	Quelle <i>et al.</i> , "Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts," <i>Genes &amp; Development</i> , 7:1559-1571 (1993)
E5	Resnitzky <i>et al.</i> , "Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system," <i>Molecular &amp; Cellular Biology</i> , 14:1669-1679 (1994)
E6	Ristimaki <i>et al.</i> , "Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C," <i>J. Biol. Chem.</i> 273(14):8413-8418 (1998)
E7	Rosenblatt <i>et al.</i> , "Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A," <i>Proc. Nat Acad. Sc. USA</i> , 89:2824-2828 (1992)
E8	Schlessinger <i>et al.</i> , "Growth factor signaling by receptor tyrosine kinases," <i>Neuron</i> 9:383-391 (1992)
E9	Shawver <i>et al.</i> , "Receptor tyrosine kinases as targets for inhibition of angiogenesis," <i>Drug Discovery Today</i> , 2:50-63 (1997)
E10	Sherr, "Mammalian G1 cyclins," <i>Cell</i> , 73:1059-1065 (1993)
E11	Shibuya <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (ftt) closely related to the fms family," <i>Oncogene</i> 5:519-524 (1990)
E12	Shoelson, "SH2 and PTB domain interactions in tyrosine kinase signal transduction," <i>Curr. Opin. Chem. Biol.</i> 1(2): 227-234 (1997)
E13	Solomon <i>et al.</i> , "Cyclin activation of p34cdc2," <i>Cell</i> , 63:1013-1024 (1990)
E14	Solomon <i>et al.</i> , "Role of phosphorylation in p34cdc2 activation: identification of an activating kinase," <i>Molecular Biology of the Cell</i> , 3:13-27 (1992)
E15	Songyang <i>et al.</i> , "SH2 domains recognize specific phosphopeptide sequences," <i>Cell</i> 72:767-778 (1993)
E16	Songyang <i>et al.</i> , "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav," <i>Mol. Cell. Biol.</i> 14:2777-2785 (1994)
E17	Staunton <i>et al.</i> , "The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and Rhinovirus," <i>Cell</i> 61:243-254 (1990)
E18	Stone <i>et al.</i> , "Reversible, p16-mediated cell cycle arrest as protection from chemotherapy," <i>Cancer Research</i> , 56:3199-3202 (1996)
E19	Takano, <i>et al.</i> , "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase," <i>Mol. Bio. Cell</i> 4:358A (1993)
RS E20	Tanaka <i>et al.</i> , "c-CBL is downstream of c-Src in a signalling pathway necessary for bone resorption," <i>Nature</i> , 383:528-531 (1996)


Examiner

/Rei Tsang Shiao/ (05/15/2006)

Date Considered

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



MAY 05 2006

[illegible]

/Rei Tsang Shiao/ (05/15/2006)

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.